Objective: To identify the prevalence of high HIV transmission potential in a cohort of youth living with HIV (YLWH), and determine the impact of insurance coverage on potential for HIV transmission.
Introduction
Despite recent decreases in HIV incidence in adolescents and young adults, youth remain less likely than older adults to know their HIV diagnosis, link to and be retained in HIV care, receive antiretroviral therapy (ART) and achieve virologic suppression. Sexual transmission of HIV may occur whenever individuals with viremia engage in sex not protected by condoms or whenever partners are not on HIV preexposure prophylaxis (PrEP). Although suppression of the HIV viral load can virtually eliminate the risk of sexual HIV transmission [1, 2] , recent data from the Centers Disease Control and Prevention (CDC) demonstrate that only 27% of youth living with HIV (YLWH) in the United States achieve virologic suppression [3] . In adults, prior studies have identified a positive association between younger age and secondary transmission risk [4, 5] . Age disparities in the HIV care continuum translate into not only poor health outcomes for YLWH but also a greater risk for secondary HIV transmission.
In order to decrease population HIV incidence, there is a critical need to identify modifiable risk factors for secondary HIV transmission among YLWH and target these factors for intervention. Prior data demonstrate the roles that comorbid conditions including depression and substance abuse play in transmission risk [5] [6] [7] [8] . However, little data exist examining the potential role of health services, such as insurance, in reducing HIV transmission risk. Insurance coverage has been associated with increased rates of ART prescription, testing and treatment for sexually transmitted infections (STI) and improved retention in care for people living with HIV. However, insurance coverage rates are lower for YLWH compared with older adults [9] . Uninsured YLWH may have limited access to ART, which is critical to achieving HIV suppression. In addition, lack of insurance may lead to delayed diagnosis and treatment of STIs, thereby increasing genital tract inflammation and HIV RNA concentrations and potentiating transmission [10, 11] .
For YLWH in the United States, coverage for ART and HIV-related medical care may be provided through private insurance, public insurance (Medicaid, Medicare) or HIV-specific limited coverage through the Ryan White HIV/AIDS Programs. Ryan White is a federally funded program that has served as a safety net for lowincome uninsured and underinsured individuals for over 25 years. Over 50% of people living with HIV in the United States receive benefits through Ryan White, either indirectly through funding to clinics for subsidized medical care or directly by no-cost ART access through the AIDS Drug Assistance Program (ADAP) [12] . If ART access is a critical driver of transmission, we hypothesized that pharmaceutical-only coverage, as well as traditional insurance, should have a protective effect against the risk of secondary HIV transmission. Therefore, our primary aims were to identify the proportion of patients meeting criteria for high HIV transmission potential within a cohort of YLWH from 2002 to 2015 and to assess associations between insurance coverage and transmission potential in this cohort.
Methods

Study design
We conducted a retrospective cohort study of YLWH receiving care at the Children's Hospital of Philadelphia (CHOP) Adolescent Initiative HIV clinic from January 2002 through June 2015.
Participants and setting
The Adolescent Initiative clinic is constituted of a multidisciplinary research and clinical team, providing care to YLWH, aged 12-26 years. Patients are seen for visits approximately every 3 months including medical assessments, HIV RNA quantification, STI screening, ART adherence counseling and intensive medical case management. The clinic's registry contains data from all individuals (n ¼ 436) receiving care during the study period. Individuals were included in the study if they attended at least two visits, were prescribed ART and had at least one plasma HIV RNA quantification after ART start. The current analysis included all visits with plasma HIV RNA quantification after the first documented date of ART in the registry. The study was approved by the CHOP Institutional Review Board, with a waiver of informed consent.
Measures
HIV transmission potential
The primary outcome of high HIV transmission potential, was defined as time-concurrent plasma HIV RNA quantification more than 1500 copies/ml (log 10 >3.17) and incident bacterial STI. As STIs lead to genital tract inflammation and may increase HIV RNA in genital tract secretions, STI functioned as a biomarker of both condomless intercourse and heightened transmission risk [10, 11] . We required both viremia and bacterial STI as the endpoint of interest because STI in the absence of viremia has not been demonstrated to confer an increased transmission risk [2, 13] . The HIV RNA threshold was selected based on prior studies demonstrating increased transmission risk in serodiscordant heterosexual couples at this level [14, 15] . To avoid bias from self-reported sexual behavior, we used laboratory-confirmed incident bacterial STI as our proxy measure for high-risk sexual behavior. Per clinic protocol, patients were screened at baseline and every 3 months, irrespective of symptoms, for syphilis via rapid plasma regain (RPR) and for gonorrhea and chlamydia by urine, oral and rectal nucleic acid amplification tests (NAAT). Patients may have refused testing at specific anatomic sites based on sexual risk behavior. As the clinic was Ryan White funded, no additional expense was incurred by uninsured individuals for having multiple sites screened or having STI testing more frequently than every 3 months.
Incident bacterial STI was defined per CDC STI treatment guidelines [16] as any of the following after the baseline visit: positive NAAT of urine, rectal and/or oral fluid for Neisseria gonorrhea or Chlamydia trachomatis, newly positive RPR with confirmatory positive treponemal test, four-fold rise in RPR titer and/or failure to achieve four-fold decrease in RPR titers within 12 months of treatment. We did not include herpes simplex virus (HSV) in the definition of transmission potential, as we were unable in the retrospective data to distinguish incident HSV infection, which would be a marker of condomless sex, from reactivation disease, which may have no relationship to sexual behavior. In addition, most diagnoses of HSV were clinical, and not laboratory-confirmed either at baseline or subsequent visits. For visits wherever STI testing was obtained and HIV RNA was not, we imputed the value for HIV RNA results obtained within 180 days of the STI testing. If HIV RNA assay results were available within both the 180 days before and after the visit, the mean of the two log 10 HIV RNA values was imputed to the STI-testing visit.
Insurance status
The primary exposure was insurance coverage, measured at each visit based on appointment registration data. Prior research examining the impact of insurance on HIVrelated outcomes has typically defined insurance as public or private insurance and considered ADAP pharmacyonly coverage as uninsured [9, 17] . However, in our causal pathway toward transmission potential, we hypothesized that pharmacy-only coverage would operate differently than total lack of coverage (neither medical nor pharmacy benefits) by allowing ongoing access to ART. Therefore, in primary analyses, we defined private insurance, public insurance (Medicaid) and ADAP pharmacy-only coverage as insured and total lack of coverage as uninsured. To test that our findings were robust to varying definitions of coverage, we performed a secondary analysis utilizing a dichotomized insurance coverage definition wherein ADAP pharmacy-only coverage was considered uninsured.
Retention in care
Prior studies have demonstrated associations between insurance and retention, insurance and virologic failure and retention and virologic failure [18, 20] . Ryan White pharmacy benefits in Pennsylvania require re-application every 6 months. Therefore, we hypothesized that retention in care would function as a time-dependent confounder in the relationship between insurance and HIV transmission potential by allowing case managers to assist with insurance applications and by its other positive effects on virologic outcomes (e.g. increased medication adherence counseling) [18, 19] . We measured retention in care with the time-varying visit adherence ratio, calculated at each visit as the total number of completed visits divided by the total number of scheduled visits to date. Visits were defined as visits with a medical provider, as well as combined laboratory and case management visits. The visit adherence ratio has the strength of capturing missed visits, a known predictor of both virologic failure and mortality in HIV [20, 21] . The ratio also accounts for disease severity, as patients with more advanced disease or psychosocial complexity are scheduled at more frequent intervals [22] . As an additional retention measure, we identified presence or absence of gaps in care more than 6 months immediately preceding each visit.
Demographics
Gender was defined by self-reported gender at the final visit, in order to account for developmental trajectories in which youth may identify gender differently throughout the study period [23, 24] . Mode of HIV acquisition was dichotomized as behavioral (via sexual behavior or injection drug use) or nonbehavioral (perinatally acquired). Race was self-reported. Baseline STI status was determined by self-report of STI prior to HIV diagnosis or a laboratory-confirmed STI at the baseline clinic visit.
Psychosocial covariates
As mental health has been demonstrated to impact both virologic suppression and transmission risk, we included a covariate in the model for a lifetime history of mental illness [7, 8, 25] . This definition included self-report of prior mental health treatment at baseline, or chartdocumented diagnosis of mental illness or suicide attempt a by a medical provider (MD, nurse practitioner or social worker) during their time in HIV care. In addition, as homelessness may impact engagement in HIV care, insurance status and treatment outcomes [26] , we included a covariate for history of unstable housing after ART initiation. Unstable housing was defined as not having a primary residence, and included staying with friends, transient housing, group home or foster care, incarceration, or homelessness. Whenever mental health and unstable housing variables were not recorded, we included the risk factor as being absent. In order to assess the robustness of this approach, we performed a secondary analysis in which we only included participants for whom these data were complete.
Data analysis
Chi-squared and Wilcoxon rank sum tests compared baseline characteristics and overall retention in care between participants with and without at least one episode of high transmission potential.
To determine the association between insurance status and high HIV transmission potential for all clinic visits, we utilized marginal structural modeling adjusting for baseline covariates and time-varying retention in care [27, 28] . To minimize the hypothesized time-dependent confounding among insurance, retention in care and transmission potential, we used an inverse probability treatment-weighted (IPTW) model [27, 29] . To estimate the stabilized weights for insurance coverage, we utilized a multivariable logistic regression model examining the probability of participants receiving their observed insurance status at each visit given their time-varying visit adherence ratio, and baseline race, age, sex, transmission route and baseline STI status. We then performed logistic regression analyses on the weighted dataset with clustering by subject to determine the odds of high transmission potential at the visit level by insurance status, adjusting for visit adherence, race, sex, age at and time from ART initiation and baseline STI. We excluded five individuals from the weighted analysis in which ART start date could not be definitively established.
In secondary analyses, we repeated the modelling, utilizing an alternate definition of insurance coverage, wherein ADAP pharmacy-only coverage was considered uninsured. Lastly, as the virologic threshold for transmission through anal intercourse is unknown and may be less than 1500 copies/ml, we performed a sensitivity analysis in which the outcome was defined as co-occurring quantitative HIV RNA greater than 200 copies/ml (log 10 >2.03) and incident STI.
Statistical analyses were conducted using the software program Stata 14.1 (StataCorp, College Station, Texas, USA) and statistical significance was set at P < 0.05.
Results
There were 240 participants (55% of total cohort, Fig. 1 ) who met our inclusion criteria and were followed for a median of 22 months after ART initiation (IQR 8. Participants were predominately African-American men and transgender women who have sex with men, with a median age at entry to care of 19 years (IQR 17-21; Table 1 ). Nearly half the participants had an STI at or before entry to care. Participants were insured at 84% (n ¼ 2241) of visits, with the breakdown of coverage type being 18% private, 59% Medicaid, 7% ADAP pharmacyonly coverage and 16% uninsured (no medical or pharmacy benefits). Although 228 (95%) of participants obtained some form of insurance during the study period, loss of coverage was experienced at least once by 65 participants (27%). The median visit adherence ratio was 0.72 (IQR 0.55-0.88), with 28% of participants experiencing at least one gap in care at least 6 months.
With respect to HIV transmission risk, incident STI was detected at least once in 123 (51%) participants after ART initiation, with at least one incident STI occurring at 286 (11%) of visits. There were 144 episodes of chlamydia, 154 episodes of gonorrhea and 37 episodes of incident syphilis. Multisite infection with a single pathogen occurred in 8% of chlamydial infections and 18% of the gonococcal infections. The most common sites of gonococcal infection were oropharyngeal (n ¼ 85) and rectal (n ¼ 75). The most common sites of chlamydial infection were rectal (n ¼ 94) and urethral (n ¼ 41). Multiorganism infection occurred commonly, with n ¼ 48 (17%) of STI episodes involving more than one pathogen. Viremia more than 1500 copies/ml was detected at least once in 110 (46%) participants and 762 (32%) visits during the study period.
High HIV transmission potential occurred at least once in 37 (15%) participants and 3% of all visits (Fig. 1) . In the bivariate analysis (Table 1) , there were no significant differences between those with or without an episode of high transmission potential with respect to age at entry to care, baseline insurance status, race, gender, lifetime history of mental illness, history of unstable housing or retention in care.
The results of the marginal structural model examining the impact of insurance coverage on transmission potential are displayed in Table 2 . After adjusting for race, age at and time from ART initiation, sex and baseline STI status, the odds of high HIV transmission potential was reduced by more than half among participants with insurance coverage (public, private or ADAP-only) compared with those without insurance. Those with a history of STI diagnosed at or before entry to HIV care, however, had more than three-fold higher adjusted odds of high HIV transmission potential during the period in care, whereas retention in care was not associated with high transmission potential. In our sensitivity analysis, wherever missing data was approached as a complete case analysis, there were neither substantive changes in the point estimates or the P values of the associations. The results of the secondary analysis, wherein ADAP pharmacy-only coverage was considered as lack of coverage, are displayed in Table 3 . Insurance coverage remained protective against high HIV transmission potential, although the association did not achieve statistical significance.
In our sensitivity analysis using a lower virologic threshold for high transmission potential, 47 participants (19%) met the definition of high transmission potential at least once in the study period. Insurance coverage remained protective against high HIV transmission potential [adjusted odds ratio (aOR) 0.55, 95% confidence interval (CI) 0.30-0.99] and baseline STI status remained highly associated with high HIV transmission potential (aOR 3.11, 95% CI 1.59-6.09) in these analyses.
Discussion
Our findings demonstrate a protective effect of insurance, whenever defined as both conventional and ADAP pharmacy-only coverage, on HIV transmission risk among a cohort of YLWH over a 13-year period. These findings underscore the critical role that insurance coverage, including ADAP benefits, plays in controlling the ongoing US HIV epidemic. At a time whenever access to health insurance is at risk in the United States [30] , maintaining funding for HIV-related medical and pharmaceutical coverage provides an essential public health safety net, not only promoting the health of people living with HIV but also preventing incident HIV infections.
The mechanism for the protective effect of insurance on transmission potential is likely multifactorial. In addition to providing ART coverage, insurance may keep patients linked to care and provide ongoing access to harm reduction counseling, both of which may lower transmission risk. As substance abuse and mental illness can be barriers to care, insurance may improve HIV-related outcomes by providing treatment for these conditions, thus reducing sexual risk behavior and improving ART adherence. Interestingly, a 2015 study of individuals in a re-linkage to care program in Washington by Dombrowski et al. found that insurance was the most common barrier cited by patients who had been lost to care, despite nearuniversal access to HIV care through Ryan White-funded clinics in the study region. These data suggest that people living with HIV may not be aware that they can continue accessing HIV care after insurance loss.
Notably, when we categorized ADAP pharmacy-only coverage as uninsured, the association between insurance and transmission potential was weaker and no longer statistically significant. This suggests that no-cost ART coverage may be a primary mechanism by which insurance decreases transmission risk. This finding is supported by a 2016 study of Medical Monitoring Project data by Bradley et al. [31] , which identified higher rates of virologic suppression in patients with Ryan White-only coverage than those with Medicaid.
Our findings emerge at a time when the future of universal coverage for ART and HIV-related medical care is uncertain. Federal Ryan White funding for ADAP is proposed to be maintained at current levels; however, if there were to be significant reductions in Medicaid access for people living with HIV, the burden placed on Ryan White to provide essential medical and pharmaceutical services would likely grow, making the current level of funding insufficient [30] .
We also identified that history of STI at or before entry to HIV care was associated with an approximately three-fold increase in the odds of high HIV transmission potential. [33] , this likely resulted in imputation of suppressed HIV RNA results to visits wherever individuals were not suppressed. Therefore, our findings likely underestimate the proportion of participants with high HIV transmission potential. However, as selfreported condomless sex may be biased, our use of STI as a biomarker for sexual risk acts to minimize outcome misclassification. In addition, we included syphilis in our definition of incident bacterial STI, yet this infection may be transmitted in the absence of condomless sex (i.e. via oral contact). However, as syphilis has been highly associated with HIV transmission risk [34] , we felt that exclusion of syphilis from the outcome definition could result in an underreporting of transmission potential in our already conservative model. Lastly, we did not include HSV in our definition of high transmission potential because of our inability to distinguish between primary infection and reactivation disease nor is it a routinely laboratory-confirmed diagnosis, which also could have lead to an under-estimation of the prevalence of incident STI in the cohort.
This study was performed exclusively among YLWH linked to care and prescribed ART at a single US clinic, and therefore results may not be generalizable to the larger US HIV epidemic or youth at different states of the HIV care continuum. However, the sociodemographic characteristics of the cohort are reflective of the current US youth HIV epidemic. Finally, the marginal structural model assumption of ignorability requires that there is no unmeasured confounding in the model. Although it is possible that there are characteristics of participants that may influence transmission potential that are not measured within our data, such as substance abuse, these variables are highly associated with retention in care [21] , and our retention measure may thus act as a proxy for these covariates. Although substance use data was included in the database, the proportion of missing data precluded inclusion of this covariate. However, in sensitivity analyses addressing the missing substance use values after ART initiation, there was minimal effect on the point estimate for the association between insurance coverage and transmission risk. Thus, it is unlikely that unmeasured substance use accounts for a significant amount of the variation in transmission risk within this cohort.
In conclusion, we identified a protective effect of insurance coverage, including HRSA Ryan White ADAP pharmacy-only coverage, on HIV secondary transmission risk among a cohort of YLWH. These findings underscore the need to maintain access to health insurance and universal ART coverage for YLWH in order to improve health outcomes and decrease transmission risk.
